REVIEW
Diagnostic and prognostic molecular biomarkers for prostate cancer
Glen Kristiansen,
Glen Kristiansen
Institute of Pathology, University Hospital Bonn, Bonn, Germany
Search for more papers by this authorGlen Kristiansen,
Glen Kristiansen
Institute of Pathology, University Hospital Bonn, Bonn, Germany
Search for more papers by this authorG Kristiansen, Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany. e-mail: [email protected]
Abstract
Kristiansen G (2012) Histopathology 60, 125–141
Diagnostic and prognostic molecular biomarkers for prostate cancer
Prostate cancer is the most common malignant tumour in men and is a major research focus of pathologists, urologists and uro-oncologists alike. The pathologist is confronted with an increasing number of biospsies, necessitating ancillary tests in morphologically challenging cases. Next to basal cell markers, additional positive markers that aid in the differential diagnosis are presented here. The clinical decision of urologists, whom and how to treat these men, is dependent predominantly on pathological parameters, but still the grid spanned by these is too wide to allow a sufficient prognostication of the individual case. Here, a brief and critical overview is given of recent developments of prognostic biomarkers in prostate cancer.
References
- 1 Jemal A , Bray F , Center MM , Ferlay J , Ward E , Forman D . Global cancer statistics . CA Cancer J. Clin. 2011 ; 61 ; 69 – 90 .
- 2 Egevad L , Allsbrook WC Jr , Epstein JI . Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists . Hum. Pathol. 2006 ; 37 ; 292 – 297 .
- 3 Galanina N , Bossuyt V , Harris LN . Molecular predictors of response to therapy for breast cancer . Cancer J. 2011 ; 17 ; 96 – 103 .
- 4 Linardou H , Dahabreh IJ , Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer . Lancet Oncol. 2008 ; 9 ; 962 – 972 .
- 5 Winder T , Lenz HJ . Molecular predictive and prognostic markers in colon cancer . Cancer Treat. Rev. 2010 ; 36 ; 550 – 556 .
- 6 Dadras SS . Molecular diagnostics in melanoma: current status and perspectives . Arch. Pathol. Lab. Med. 2011 ; 135 ; 860 – 869 .
- 7 Totten RS , Heinemann MW , Hudson PB , Sproul EE , Stout AP . Microscopic differential diagnosis of latent carcinoma of prostate . AMA Arch. Pathol. 1953 ; 55 ; 131 – 141 .
- 8 Thorson P , Humphrey PA . Minimal adenocarcinoma in prostate needle biopsy tissue . Am. J. Clin. Pathol. 2000 ; 114 ; 896 – 909 .
- 9 Epstein JI . Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy . Mod. Pathol. 2004 ; 17 ; 307 – 315 .
- 10 Brawer MK , Peehl DM , Stamey TA , Bostwick DG . Keratin immunoreactivity in the benign and neoplastic human prostate . Cancer Res. 1985 ; 45 ; 3663 – 3667 .
- 11 Hedrick L , Epstein JI . Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma . Am. J. Surg. Pathol. 1989 ; 13 ; 389 – 396 .
- 12 Signoretti S , Waltregny D , Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development . Am. J. Pathol. 2000 ; 157 ; 1769 – 1775 .
- 13 Weinstein MH , Signoretti S , Loda M . Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells . Mod. Pathol. 2002 ; 15 ; 1302 – 1308 .
- 14 Shah RB , Zhou M , LeBlanc M , Snyder M , Rubin MA . Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer . Am. J. Surg. Pathol. 2002 ; 26 ; 1161 – 1168 .
- 15 Zhou M , Shah R , Shen R , Rubin MA . Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells . Am. J. Surg. Pathol. 2003 ; 27 ; 365 – 371 .
- 16 Oliai BR , Kahane H , Epstein JI . Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody . Am. J. Surg. Pathol. 2002 ; 26 ; 1151 – 1160 .
- 17 Ali TZ , Epstein JI . False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells . Am. J. Surg. Pathol. 2008 ; 32 ; 1890 – 1895 .
- 18 Osunkoya AO , Hansel DE , Sun X , Netto GJ , Epstein JI . Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases . Am. J. Surg. Pathol. 2008 ; 32 ; 461 – 467 .
- 19 Kuroda N , Katto K , Tamura M et al. Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials . Med. Mol. Morphol. 2010 ; 43 ; 165 – 169 .
- 20 Hasegawa M , Hagiwara S , Sato T et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells . Pathol. Int. 2007 ; 57 ; 245 – 250 .
- 21 Jarrard DF , Paul R , van Bokhoven A et al. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer . Clin. Cancer Res. 1997 ; 3 ; 2121 – 2128 .
- 22 Ramos Soler D , Mayordomo Aranda E , Calatayud Blas A , Rubio Briones J , Solsona Narbon E , Llombart Bosch A . Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology . Actas Urol. Esp. 2006 ; 30 ; 345 – 352 .
- 23 Beckett ML , Wright GL Jr . Characterization of a prostate carcinoma mucin-like antigen (PMA) . Int. J. Cancer 1995 ; 62 ; 703 – 710 .
- 24 Beckett ML , Lipford GB , Haley CL , Schellhammer PF , Wright GL Jr . Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas . Cancer Res. 1991 ; 51 ; 1326 – 1333 .
- 25 Xu J , Stolk JA , Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray . Cancer Res. 2000 ; 60 ; 1677 – 1682 .
- 26 Jiang Z , Woda BA , Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma . Am. J. Surg. Pathol. 2001 ; 25 ; 1397 – 1404 .
- 27 Rubin MA , Zhou M , Dhanasekaran SM et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer . JAMA 2002 ; 287 ; 1662 – 1670 .
- 28 Kunju LP , Chinnaiyan AM , Shah RB . Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer . Histopathology 2005 ; 47 ; 587 – 596 .
- 29 Luo J , Zha S , Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer . Cancer Res. 2002 ; 62 ; 2220 – 2226 .
- 30 Lloyd MD , Darley DJ , Wierzbicki AS , Threadgill MD . Alpha-methylacyl-CoA racemase – an ‘obscure’ metabolic enzyme takes centre stage . FEBS J. 2008 ; 275 ; 1089 – 1102 .
- 31 Went PT , Sauter G , Oberholzer M , Bubendorf L . Abundant expression of AMACR in many distinct tumour types . Pathology 2006 ; 38 ; 426 – 432 .
- 32 Dorer R , Odze RD . AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis, and Crohn’s disease . Am. J. Surg. Pathol. 2006 ; 30 ; 871 – 877 .
- 33 Sonwalkar SA , Rotimi O , Scott N et al. A study of indefinite for dysplasia in Barrett’s oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase) . Histopathology 2010 ; 56 ; 900 – 907 .
- 34 Carswell BM , Woda BA , Wang X , Li C , Dresser K , Jiang Z . Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy . Histopathology 2006 ; 48 ; 668 – 673 .
- 35 Farinola MA , Epstein JI . Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy . Hum. Pathol. 2004 ; 35 ; 1272 – 1278 .
- 36 Herawi M , Epstein JI . Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate . Am. J. Surg. Pathol. 2007 ; 31 ; 889 – 894 .
- 37 Jiang Z , Wu CL , Woda BA et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker . Histopathology 2004 ; 45 ; 218 – 225 .
- 38 Zhou M , Aydin H , Kanane H , Epstein JI . How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am. J. Surg. Pathol. 2004 ; 28 ; 239 – 243 .
- 39 Paner GP , Luthringer DJ , Amin MB . Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies . Arch. Pathol. Lab. Med. 2008 ; 132 ; 1388 – 1396 .
- 40 Jiang Z , Iczkowski KA , Woda BA , Tretiakova M , Yang XJ . P504S immunostaining boosts diagnostic resolution of ‘suspicious’ foci in prostatic needle biopsy specimens . Am. J. Clin. Pathol. 2004 ; 121 ; 99 – 107 .
- 41 Herawi M , Parwani AV , Irie J , Epstein JI . Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion . Am. J. Surg. Pathol. 2005 ; 29 ; 874 – 880 .
- 42 Wang W , Sun X , Epstein JI . Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study . Am. J. Surg. Pathol. 2008 ; 32 ; 851 – 857 .
- 43 Murphy AJ , Hughes CA , Lannigan G , Sheils O , O’Leary J , Loftus B . Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score . Histopathology 2007 ; 50 ; 243 – 251 .
- 44 Gologan A , Bastacky S , McHale T et al. Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues . Am. J. Surg. Pathol. 2005 ; 29 ; 1435 – 1441 .
- 45 Kristiansen G , Fritzsche FR , Wassermann K et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics . Br. J. Cancer 2008 ; 99 ; 939 – 948 .
- 46 Ananthanarayanan V , Deaton RJ , Yang XJ , Pins MR , Gann PH . Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer . Prostate 2005 ; 63 ; 341 – 346 .
- 47 Wu CL , Yang XJ , Tretiakova M et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia . Hum. Pathol. 2004 ; 35 ; 1008 – 1013 .
- 48 Bachert C , Fimmel C , Linstedt AD . Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma . Traffic 2007 ; 8 ; 1415 – 1423 .
- 49 Iftikhar R , Kladney RD , Havlioglu N et al. Disease- and cell-specific expression of GP73 in human liver disease . Am. J. Gastroenterol. 2004 ; 99 ; 1087 – 1095 .
- 50 Kladney RD , Bulla GA , Guo L et al. GP73, a novel Golgi-localized protein upregulated by viral infection . Gene 2000 ; 249 ; 53 – 65 .
- 51 Kladney RD , Cui X , Bulla GA , Brunt EM , Fimmel CJ . Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease . Hepatology 2002 ; 35 ; 1431 – 1440 .
- 52 Marrero JA , Romano PR , Nikolaeva O et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma . J. Hepatol. 2005 ; 43 ; 1007 – 1012 .
- 53 Luo JH , Yu YP , Cieply K et al. Gene expression analysis of prostate cancers . Mol. Carcinog. 2002 ; 33 ; 25 – 35 .
- 54 Lapointe J , Li C , Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer . Proc. Natl Acad. Sci. USA 2004 ; 101 ; 811 – 816 .
- 55 Kristiansen G , Pilarsky C , Wissmann C et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival . J. Pathol. 2005 ; 205 ; 359 – 376 .
- 56 Wei S , Dunn TA , Isaacs WB , De Marzo AM , Luo J . GOLPH2 and MYO6: putative prostate cancer markers localized to the golgi apparatus . Prostate 2008 ; 68 ; 1387 – 1395 .
- 57 Varambally S , Laxman B , Mehra R et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer . Neoplasia 2008 ; 10 ; 1285 – 1294 .
- 58 Menendez JA , Lupu R . Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis . Nat. Rev. Cancer 2007 ; 7 ; 763 – 777 .
- 59 Warburg O . On the origin of cancer cells . Science 1956 ; 123 ; 309 – 314 .
- 60 Prowatke I , Devens F , Benner A et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays . Br. J. Cancer 2007 ; 96 ; 82 – 88 .
- 61 Shurbaji MS , Kalbfleisch JH , Thurmond TS . Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer . Hum. Pathol. 1996 ; 27 ; 917 – 921 .
- 62 Baron A , Migita T , Tang D , Loda M . Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem. 2004 ; 91 ; 47 – 53 .
- 63 Fiorentino M , Zadra G , Palescandolo E et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer . Lab. Invest. 2008 ; 88 ; 1340 – 1348 .
- 64 Migita T , Ruiz S , Fornari A et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer . J. Natl Cancer Inst. 2009 ; 101 ; 519 – 532 .
- 65 Rossi S , Graner E , Febbo P et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer . Mol. Cancer Res. 2003 ; 1 ; 707 – 715 .
- 66 Tischler V , Fritzsche FR , Gerhardt J et al. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker . Histopathology 2010 ; 56 ; 811 – 815 .
- 67 Wu X , Zayzafoon M , Zhang X , Hameed O . Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: a comparison with AMACR . Am. J. Clin. Pathol. 2011 ; 136 ; 239 – 246 .
- 68 Tomlins SA , Rhodes DR , Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer . Science 2005 ; 310 ; 644 – 648 .
- 69 Demichelis F , Fall K , Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort . Oncogene 2007 ; 26 ; 4596 – 4599 .
- 70 Clark JP , Cooper CS . ETS gene fusions in prostate cancer . Nat. Rev. Urol. 2009 ; 6 ; 429 – 439 .
- 71 Park K , Tomlins SA , Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer . Neoplasia 2010 ; 12 ; 590 – 598 .
- 72 Miettinen M , Wang ZF , Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma . Am. J. Surg. Pathol. 2011 ; 35 ; 432 – 441 .
- 73 Wang J , Cai Y , Ren C , Ittmann M . Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer . Cancer Res. 2006 ; 66 ; 8347 – 8351 .
- 74 van Leenders GJ , Boormans JL , Vissers CJ et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice . Mod. Pathol. 2011 ; 24 ; 1128 – 1138 .
- 75 Falzarano SM , Zhou M , Carver P et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry . Virchows Arch. 2011 ; 459 ; 441 – 447 .
- 76 Chaux A , Albadine R , Toubaji A et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas . Am. J. Surg. Pathol. 2011 ; 35 ; 1014 – 1020 .
- 77 He H , Magi-Galluzzi C , Li J et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with ‘atypical glands suspicious for cancer’ . Am. J. Surg. Pathol. 2011 ; 35 ; 608 – 614 .
- 78 Yaskiv O , Zhang X , Simmerman K et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies . Am. J. Surg. Pathol. 2011 ; 35 ; 1062 – 1068 .
- 79 Lapointe J , Li C , Giacomini CP et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis . Cancer Res. 2007 ; 67 ; 8504 – 8510 .
- 80 Braun M , Scheble VJ , Menon R et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer . Histopathology 2011 ; 58 ; 1028 – 1036 .
- 81 Mosquera JM , Perner S , Demichelis F et al. Morphological features of TMPRSS2–ERG gene fusion prostate cancer . J. Pathol. 2007 ; 212 ; 91 – 101 .
- 82 Fine SW , Gopalan A , Leversha MA et al. TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features . Mod. Pathol. 2010 ; 23 ; 1325 – 1333 .
- 83 Guo CC , Zuo G , Cao D , Troncoso P , Czerniak BA . Prostate cancer of transition zone origin lacks TMPRSS2–ERG gene fusion . Mod. Pathol. 2009 ; 22 ; 866 – 871 .
- 84 Bismar TA , Trpkov K . TMPRSS2–ERG gene fusion in transition zone prostate cancer . Mod. Pathol. 2010 ; 23 ; 1040 – 1041 ; author reply 1041–1042 .
- 85 Falzarano SM , Navas M , Simmerman K et al. ERG rearrangement is present in a subset of transition zone prostatic tumors . Mod. Pathol. 2010 ; 23 ; 1499 – 1506 .
- 86 Mao X , Yu Y , Boyd LK et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis . Cancer Res. 2010 ; 70 ; 5207 – 5212 .
- 87 Miyagi Y , Sasaki T , Fujinami K et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples . Mod. Pathol. 2010 ; 23 ; 1492 – 1498 .
- 88 Magi-Galluzzi C , Tsusuki T , Elson P et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients . Prostate 2011 ; 71 ; 489 – 497 .
- 89 Mosquera JM , Perner S , Genega EM et al. Characterization of TMPRSS2–ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications . Clin. Cancer Res. 2008 ; 14 ; 3380 – 3385 .
- 90 Perner S , Mosquera JM , Demichelis F et al. TMPRSS2–ERG fusion prostate cancer: an early molecular event associated with invasion . Am. J. Surg. Pathol. 2007 ; 31 ; 882 – 888 .
- 91 Haggarth L , Hagglof C , Jaraj SJ et al. Diagnostic biomarkers of prostate cancer . Scand. J. Urol. Nephrol. 2011 ; 45 ; 60 – 67 .
- 92 Petraki CD , Sfikas CP . Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma . Histol. Histopathol. 2007 ; 22 ; 107 – 118 .
- 93 Bostwick DG . Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer . Am. J. Clin. Pathol. 1994 ; 102 ; S31 – S37 .
- 94 Kraus TS , Cohen C , Siddiqui MT . Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma . Diagn. Pathol. 2010 ; 5 ; 63 .
- 95 Alanen KA , Kuopio T , Koskinen PJ , Nevalainen TJ . Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues . Pathol. Res. Pract. 1996 ; 192 ; 233 – 237 .
- 96 van Krieken JH . Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry . Am. J. Surg. Pathol. 1993 ; 17 ; 410 – 414 .
- 97 Renshaw AA , Granter SR . Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration . Diagn. Cytopathol. 2000 ; 23 ; 199 – 201 .
- 98 Wright GL Jr , Haley C , Beckett ML , Schellhammer PF . Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues . Urol. Oncol. 1995 ; 1 ; 18 – 28 .
- 99 Troyer JK , Beckett ML , Wright GL Jr . Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids . Int. J. Cancer 1995 ; 62 ; 552 – 558 .
- 100 Kinoshita Y , Kuratsukuri K , Landas S et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues . World J. Surg. 2006 ; 30 ; 628 – 636 .
- 101 Samplaski MK , Heston W , Elson P , Magi-Galluzzi C , Hansel DE . Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature . Mod. Pathol. 2011 ; 24 ; 1521 – 1529 .
- 102 Fleischmann A , Rocha C , Schobinger S , Seiler R , Wiese B , Thalmann GN . Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases . Prostate 2011 ; 71 ; 453 – 460 .
- 103 Loda M , Fogt F , French FS et al. Androgen receptor immunohistochemistry on paraffin-embedded tissue . Mod. Pathol. 1994 ; 7 ; 388 – 391 .
- 104 Jaspers HC , Verbist BM , Schoffelen R et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options . J. Clin. Oncol. 2011 ; 29 ; e473 – e476 .
- 105 Murphy CE , Carder PJ , Lansdown MR , Speirs V . Steroid hormone receptor expression in male breast cancer . Eur. J. Surg. Oncol. 2006 ; 32 ; 44 – 47 .
- 106 Xu J , Kalos M , Stolk JA et al. Identification and characterization of prostein, a novel prostate-specific protein . Cancer Res. 2001 ; 61 ; 1563 – 1568 .
- 107 Kalos M , Askaa J , Hylander BL et al. Prostein expression is highly restricted to normal and malignant prostate tissues . Prostate 2004 ; 60 ; 246 – 256 .
- 108 Sheridan T , Herawi M , Epstein JI , Illei PB . The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate . Am. J. Surg. Pathol. 2007 ; 31 ; 1351 – 1355 .
- 109 Osunkoya AO , Netto GJ , Epstein JI . Colorectal adenocarcinoma involving the prostate: report of 9 cases . Hum. Pathol. 2007 ; 38 ; 1836 – 1841 .
- 110 Chuang AY , DeMarzo AM , Veltri RW , Sharma RB , Bieberich CJ , Epstein JI . Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma . Am. J. Surg. Pathol. 2007 ; 31 ; 1246 – 1255 .
- 111 Lane Z , Hansel DE , Epstein JI . Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder . Am. J. Surg. Pathol. 2008 ; 32 ; 1322 – 1326 .
- 112 Lane Z , Epstein JI , Ayub S , Netto GJ . Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features . Hum. Pathol. 2008 ; 39 ; 543 – 549 .
- 113 Srinivasan M , Parwani AV . Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma . Diagn. Pathol. 2011 ; 6 ; 67 .
- 114 Scheble VJ , Braun M , Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor . Mod. Pathol. 2010 ; 23 ; 1061 – 1067 .
- 115 Perner S , Svensson MA , Hossain RR et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer . Urology 2010 ; 75 ; 762 – 767 .
- 116 Scheble VJ , Braun M , Wilbertz T et al. ERG rearrangement in small cell prostatic and lung cancer . Histopathology 2010 ; 56 ; 937 – 943 .
- 117 Guo CC , Dancer JY , Wang Y et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate . Hum. Pathol. 2011 ; 42 ; 11 – 17 .
- 118 Williamson SR , Zhang S , Yao JL et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin . Mod. Pathol. 2011 ; 24 ; 1120 – 1127 .
- 119 Lotan TL , Gupta NS , Wang W et al. ERG gene rearrangements are common in prostatic small cell carcinomas . Mod. Pathol. 2011 ; 24 ; 820 – 828 .
- 120 Wang W , Epstein JI . Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases . Am. J. Surg. Pathol. 2008 ; 32 ; 65 – 71 .
- 121 Voeller HJ , Augustus M , Madike V , Bova GS , Carter KC , Gelmann EP . Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers . Cancer Res. 1997 ; 57 ; 4455 – 4459 .
- 122 He WW , Sciavolino PJ , Wing J et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer . Genomics 1997 ; 43 ; 69 – 77 .
- 123 Gelmann EP , Bowen C , Bubendorf L . Expression of NKX3.1 in normal and malignant tissues . Prostate 2003 ; 55 ; 111 – 117 .
- 124 Bethel CR , Faith D , Li X et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion . Cancer Res. 2006 ; 66 ; 10683 – 10690 .
- 125 Bowen C , Bubendorf L , Voeller HJ et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression . Cancer Res. 2000 ; 60 ; 6111 – 6115 .
- 126 Gurel B , Ali TZ , Montgomery EA et al. NKX3.1 as a marker of prostatic origin in metastatic tumors . Am. J. Surg. Pathol. 2010 ; 34 ; 1097 – 1105 .
- 127 Nam RK , Kattan MW , Chin JL et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators . J. Clin. Oncol. 2011 ; 29 ; 2959 – 2964 .
- 128 Shariat SF , Kattan MW , Vickers AJ , Karakiewicz PI , Scardino PT . Critical review of prostate cancer predictive tools . Future Oncol. 2009 ; 5 ; 1555 – 1584 .
- 129 Klotz L . Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin. Radiat. Oncol. 2008 ; 18 ; 2 – 6 .
- 130 Albertsen PC , Hanley JA , Gleason DF , Barry MJ . Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer . JAMA 1998 ; 280 ; 975 – 980 .
- 131 Chodak GW , Thisted RA , Gerber GS et al. Results of conservative management of clinically localized prostate cancer . N. Engl. J. Med. 1994 ; 330 ; 242 – 248 .
- 132 Harlan SR , Cooperberg MR , Elkin EP et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE . J. Urol. 2003 ; 170 ; 1804 – 1807 .
- 133 Albertsen PC , Hanley JA , Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer . JAMA 2005 ; 293 ; 2095 – 2101 .
- 134 Lein M , Stibane I , Mansour R et al. Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies – experience at the Charite Hospital Berlin, Campus Mitte . Eur. Urol . 2006 ; 50 ; 1278 – 1282 ; discussion 1283–1274 .
- 135 Dall’Era MA , Cooperberg MR , Chan JM et al. Active surveillance for early-stage prostate cancer: review of the current literature . Cancer 2008 ; 112 ; 1650 – 1659 .
- 136 Harnden P , Naylor B , Shelley MD , Clements H , Coles B , Mason MD . The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis . Cancer 2008 ; 112 ; 971 – 981 .
- 137 Klotz L . Active surveillance for favorable risk prostate cancer: rationale, risks, and results . Urol. Oncol. 2007 ; 25 ; 505 – 509 .
- 138 Loeb S , Roehl KA , Thaxton CS , Catalona WJ . Combined prostate-specific antigen density and biopsy features to predict ‘clinically insignificant’ prostate cancer . Urology 2008 ; 72 ; 143 – 147 .
- 139 Jeldres C , Suardi N , Walz J et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men . Eur. Urol. 2008 ; 54 ; 1306 – 1313 .
- 140 van Oort IM , Kok DE , Kiemeney LA , Hulsbergen-van de Kaa CA , Witjes JA . A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or ‘insignificant’ . Urol. Oncol. 2009 ; 27 ; 509 – 513 .
- 141 Sengupta S , Blute ML , Bagniewski SM et al. After radical retropubic prostatectomy ‘insignificant’ prostate cancer has a risk of progression similar to low-risk ‘significant’ cancer . BJU Int. 2008 ; 101 ; 170 – 174 .
- 142 Chun FK , Haese A , Ahyai SA et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men . Cancer 2008 ; 113 ; 701 – 709 .
- 143 Stamatiou K , Alevizos A , Mariolis A et al. Do clinically insignificant tumors of the prostate exist? Urol. Int. 2008 ; 81 ; 379 – 382 .
- 144 Perner S , Demichelis F , Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer . Cancer Res. 2006 ; 66 ; 8337 – 8341 .
- 145 Nam RK , Sugar L , Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression . Cancer Biol. Ther. 2007 ; 6 ; 40 – 45 .
- 146 Nam RK , Sugar L , Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer . Br. J. Cancer 2007 ; 97 ; 1690 – 1695 .
- 147 Attard G , Clark J , Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer . Oncogene 2008 ; 27 ; 253 – 263 .
- 148 Yoshimoto M , Joshua AM , Cunha IW et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome . Mod. Pathol. 2008 ; 21 ; 1451 – 1460 .
- 149 Sboner A , Demichelis F , Calza S et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression . BMC Med. Genomics 2010 ; 3 ; 8 .
- 150 Winnes M , Lissbrant E , Damber JE , Stenman G . Molecular genetic analyses of the TMPRSS2–ERG and TMPRSS2–ETV1 gene fusions in 50 cases of prostate cancer . Oncol. Rep. 2007 ; 17 ; 1033 – 1036 .
- 151 Saramaki OR , Harjula AE , Martikainen PM , Vessella RL , Tammela TL , Visakorpi T . TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis . Clin. Cancer Res. 2008 ; 14 ; 3395 – 3400 .
- 152 Boormans JL , Porkka K , Visakorpi T , Trapman J . Confirmation of the association of TMPRSS2(exon 0): ERG expression and a favorable prognosis of primary prostate cancer . Eur. Urol. 2011 ; 60 ; 183 – 184 .
- 153 Hermans KG , Boormans JL , Gasi D et al. Overexpression of prostate-specific TMPRSS2(exon 0)–ERG fusion transcripts corresponds with favorable prognosis of prostate cancer . Clin. Cancer Res. 2009 ; 15 ; 6398 – 6403 .
- 154 Furusato B , Gao CL , Ravindranath L et al. Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer . Mod. Pathol. 2008 ; 21 ; 67 – 75 .
- 155 FitzGerald LM , Agalliu I , Johnson K et al. Association of TMPRSS2–ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer . BMC Cancer 2008 ; 8 ; 230 .
- 156 Esgueva R , Perner S , LaFargue C et al. Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohort . Mod. Pathol. 2010 ; 23 ; 539 – 546 .
- 157 Gopalan A , Leversha MA , Satagopan JM et al. TMPRSS2–ERG gene fusion is not associated with outcome in patients treated by prostatectomy . Cancer Res. 2009 ; 69 ; 1400 – 1406 .
- 158 Minner S , Enodien M , Sirma H et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy . Clin. Cancer Res. 2011 ; 17 ; 5878 – 5888 .
- 159 Toubaji A , Albadine R , Meeker AK et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas . Mod. Pathol. 2011 ; 24 ; 1511 – 1520 .
- 160 Ward JF , Blute ML , Slezak J , Bergstralh EJ , Zincke H . The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy . J. Urol. 2003 ; 170 ; 1872 – 1876 .
- 161 Carver BS , Bianco FJ Jr , Scardino PT , Eastham JA . Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer . J. Urol. 2006 ; 176 ; 564 – 568 .
- 162 Porter CR , Kodama K , Gibbons RP et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series . J. Urol. 2006 ; 176 ; 569 – 574 .
- 163 Lee SE , Currin SM , Paulson DF , Walther PJ . Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence . J. Urol. 1988 ; 140 ; 769 – 774 .
- 164 Stephenson RA , James BC , Gay H , Fair WR , Whitmore WF Jr , Melamed MR . Flow cytometry of prostate cancer: relationship of DNA content to survival . Cancer Res. 1987 ; 47 ; 2504 – 2507 .
- 165 Frankfurt OS , Chin JL , Englander LS , Greco WR , Pontes JE , Rustum YM . Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer . Cancer Res. 1985 ; 45 ; 1418 – 1423 .
- 166 Berger MF , Lawrence MS , Demichelis F et al. The genomic complexity of primary human prostate cancer . Nature 2011 ; 470 ; 214 – 220 .
- 167 Jeronimo C , Bastian PJ , Bjartell A et al. Epigenetics in prostate cancer: biologic and clinical relevance . Eur. Urol. 2011 ; 60 ; 753 – 766 .
- 168 Jones PA , Baylin SB . The epigenomics of cancer . Cell 2007 ; 128 ; 683 – 692 .
- 169 Lin X , Tascilar M , Lee WH et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells . Am. J. Pathol. 2001 ; 159 ; 1815 – 1826 .
- 170 Jeronimo C , Henrique R , Hoque MO et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker . Clin. Cancer Res. 2004 ; 10 ; 4010 – 4014 .
- 171 Henrique R , Ribeiro FR , Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients . Clin. Cancer Res. 2007 ; 13 ; 6122 – 6129 .
- 172 Weiss G , Cottrell S , Distler J et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy . J. Urol. 2009 ; 181 ; 1678 – 1685 .
- 173 Liu L , Kron KJ , Pethe VV et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3, and RASSF1A with prostate cancer progression . Int. J. Cancer 2011 ; 129 ; 2454 – 2462 .
- 174 Kron KJ , Liu L , Pethe VV et al. DNA methylation of HOXD3 as a marker of prostate cancer progression . Lab. Invest. 2010 ; 90 ; 1060 – 1067 .
- 175 Banez LL , Sun L , van Leenders GJ et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer . J. Urol. 2010 ; 184 ; 149 – 156 .
- 176 Schatz P , Dietrich D , Koenig T et al. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation . J. Mol. Diagn. 2010 ; 12 ; 345 – 353 .
- 177 Vinarskaja A , Schulz WA , Ingenwerth M , Hader C , Arsov C . Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis . Urol. Oncol. 2011 ; [Epub ahead of print] DOI: org/10.1016/j.urolonc.2011.04.010.
- 178 Iorio MV , Croce CM . MicroRNAs in cancer: small molecules with a huge impact . J. Clin. Oncol. 2009 ; 27 ; 5848 – 5856 .
- 179 Schaefer A , Jung M , Mollenkopf HJ et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma . Int. J. Cancer 2010 ; 126 ; 1166 – 1176 .
- 180 Leite KR , Tomiyama A , Reis ST et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer . J. Urol. 2011 ; 185 ; 1118 – 1122 .
- 181 Spahn M , Kneitz S , Scholz CJ et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence . Int. J. Cancer 2010 ; 127 ; 394 – 403 .
- 182 Martens-Uzunova ES , Jalava SE , Dits NF et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer . Oncogene 2011 ; [Epub ahead of print] DOI: 10.1038/onc.2011.304.
- 183 Dhanasekaran SM , Barrette TR , Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer . Nature 2001 ; 412 ; 822 – 826 .
- 184 Varambally S , Dhanasekaran SM , Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer . Nature 2002 ; 419 ; 624 – 629 .
- 185 Henshall SM , Afar DE , Hiller J et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse . Cancer Res. 2003 ; 63 ; 4196 – 4203 .
- 186 Singh D , Febbo PG , Ross K et al. Gene expression correlates of clinical prostate cancer behavior . Cancer Cell 2002 ; 1 ; 203 – 209 .
- 187 Latil A , Bieche I , Chene L et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior . Clin. Cancer Res. 2003 ; 9 ; 5477 – 5485 .
- 188 Nanni S , Priolo C , Grasselli A et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer . Mol. Cancer Res. 2006 ; 4 ; 79 – 92 .
- 189 Glinsky GV , Glinskii AB , Stephenson AJ , Hoffman RM , Gerald WL . Gene expression profiling predicts clinical outcome of prostate cancer . J. Clin. Invest. 2004 ; 113 ; 913 – 923 .
- 190 Varambally S , Yu J , Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression . Cancer Cell 2005 ; 8 ; 393 – 406 .
- 191 Mucci LA , Pawitan Y , Demichelis F et al. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort . Cancer Epidemiol. Biomarkers Prev. 2008 ; 17 ; 249 – 251 .
- 192 Bismar TA , Demichelis F , Riva A et al. Defining aggressive prostate cancer using a 12-gene model . Neoplasia 2006 ; 8 ; 59 – 68 .
- 193 Mucci LA , Pawitan Y , Demichelis F et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort . Cancer Epidemiol. Biomarkers Prev. 2008 ; 17 ; 1682 – 1688 .
- 194 Cuzick J , Swanson GP , Fisher G et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study . Lancet Oncol. 2011 ; 12 ; 245 – 255 .
- 195 Chen JL , Li J , Stadler WM , Lussier YA . Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence . J. Am. Med. Inform. Assoc. 2011 ; 18 ; 392 – 402 .
- 196 Hanahan D , Weinberg RA . Hallmarks of cancer: the next generation . Cell 2011 ; 144 ; 646 – 674 .
- 197 Gerdes J , Schwab U , Lemke H , Stein H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation . Int. J. Cancer 1983 ; 31 ; 13 – 20 .
- 198 Stattin P , Damber JE , Karlberg L , Bergh A . Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer . J. Urol. 1997 ; 157 ; 219 – 222 .
- 199 Borre M , Bentzen SM , Nerstrom B , Overgaard J . Tumor cell proliferation and survival in patients with prostate cancer followed expectantly . J. Urol. 1998 ; 159 ; 1609 – 1614 .
- 200 Berney DM , Gopalan A , Kudahetti S et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study . Br. J. Cancer 2009 ; 100 ; 888 – 893 .
- 201
Bubendorf L
,
Sauter G
,
Moch H
et al.
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy
.
J. Pathol.
1996
;
178
;
437
–
441
.
10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 202 Bettencourt MC , Bauer JJ , Sesterhenn IA , Mostofi FK , McLeod DG , Moul JW . Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy . J. Urol. 1996 ; 156 ; 1064 – 1068 .
- 203 Sebo TJ , Cheville JC , Riehle DL et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer . Am. J. Surg. Pathol. 2002 ; 26 ; 431 – 439 .
- 204 Rubio J , Ramos D , Lopez-Guerrero JA et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens . Eur. Urol. 2005 ; 48 ; 745 – 751 .
- 205 Laitinen S , Martikainen PM , Tolonen T , Isola J , Tammela TL , Visakorpi T . EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients . Int. J. Cancer 2008 ; 122 ; 595 – 602 .
- 206 Gunia S , Albrecht K , Koch S et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability . World J. Urol. 2008 ; 26 ; 243 – 250 .
- 207 Miyake H , Muramaki M , Kurahashi T , Takenaka A , Fujisawa M . Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy . Urol. Oncol. 2010 ; 28 ; 145 – 151 .
- 208
Khoo VS
,
Pollack A
,
Cowen D
et al.
Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy
.
Prostate
1999
;
41
;
166
–
172
.
10.1002/(SICI)1097-0045(19991101)41:3<166::AID-PROS3>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 209 Cowen D , Troncoso P , Khoo VS et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy . Clin. Cancer Res. 2002 ; 8 ; 1148 – 1154 .
- 210 Pollack A , Cowen D , Troncoso P et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x . Cancer 2003 ; 97 ; 1630 – 1638 .
- 211 Pollack A , DeSilvio M , Khor LY et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02 . J. Clin. Oncol. 2004 ; 22 ; 2133 – 2140 .
- 212 Khor LY , Bae K , Paulus R et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02 . J. Clin. Oncol. 2009 ; 27 ; 3177 – 3184 .
- 213 Zellweger T , Gunther S , Zlobec I et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer . Int. J. Cancer 2009 ; 124 ; 2116 – 2123 .
- 214 Malhotra S , Lapointe J , Salari K et al. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer . PLoS One 2011 ; 6 ; e20293 .
- 215 Bubendorf L , Tapia C , Gasser TC et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer . Hum. Pathol. 1998 ; 29 ; 949 – 954 .
- 216 Vis AN , Noordzij MA , Fitoz K , Wildhagen MF , Schroder FH , van der Kwast TH . Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer . J. Urol. 2000 ; 164 ; 2156 – 2161 .
- 217 Rubin MA , Dunn R , Strawderman M , Pienta KJ . Tissue microarray sampling strategy for prostate cancer biomarker analysis . Am. J. Surg. Pathol. 2002 ; 26 ; 312 – 319 .
- 218 Li R , Heydon K , Hammond ME et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10 . Clin. Cancer Res. 2004 ; 10 ; 4118 – 4124 .
- 219 Goto T , Nguyen BP , Nakano M , Ehara H , Yamamoto N , Deguchi T . Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population . Urology 2008 ; 72 ; 167 – 171 .
Citing Literature
